Telix Pharmaceuticals (ASX:TLX) said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorization for its prostate cancer imaging agent, Illuccix, according to a Thursday filing with the Australian bourse.
The approval allows for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer through positron emission tomography imaging, the filing said.
Illuccix will be distributed in the UK through Telix's partner, Xiel, a distributor of nuclear medicine, radiotherapy, and diagnostic radiology technologies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.